ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Gross Profit for the year ending December 31, 2023: USD 50.30 M

ABL Bio Inc. Gross Profit is USD 50.30 M for the year ending December 31, 2023, a 39.76% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

ABL Bio Inc. Gross Profit for the year ending December 31, 2022 was USD 35.99 M, a 302.80% change year over year.
ABL Bio Inc. Gross Profit for the year ending December 31, 2021 was USD -17.75 M, a -518.74% change year over year.
ABL Bio Inc. Gross Profit for the year ending December 31, 2020 was USD -2.87 M, a 32.65% change year over year.
ABL Bio Inc. Gross Profit for the year ending December 31, 2019 was USD -4.26 M, a -112.30% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years